Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Barbara Valentinis"'
Autor:
Simona Porcellini, Claudia Asperti, Stefano Corna, Eleonora Cicoria, Veronica Valtolina, Anna Stornaiuolo, Barbara Valentinis, Claudio Bordignon, Catia Traversari
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
The main challenge of adoptive therapy with Chimeric Antigen Receptor modified T cells (CAR T) is the application to the field of solid tumors, where the identification of a proper antigen has emerged as one of the major drawbacks to CAR T cell treat
Externí odkaz:
https://doaj.org/article/7301d7cf04b2437fadb57727709d647a
Autor:
Barbara Valentinis, Simona Porcellini, Claudia Asperti, Manuela Cota, Dan Zhou, Paola Di Matteo, Gianpiero Garau, Chiara Zucchelli, Nilla Roberta Avanzi, Gian Paolo Rizzardi, Massimo Degano, Giovanna Musco, Catia Traversari
Publikováno v:
International Journal of Molecular Sciences, Vol 20, Iss 18, p 4511 (2019)
NGR-hTNF is a therapeutic agent for a solid tumor that specifically targets angiogenic tumor blood vessels, through the NGR motif. Its activity has been assessed in several clinical studies encompassing tumors of different histological types. The dru
Externí odkaz:
https://doaj.org/article/a7d2cbef867641d2a8759c309b9ea9cf
Autor:
Claudia Asperti, Barbara Valentinis, Simona Porcellini, Eleonora Cicoria, Catia Traversari, Anna Stornaiuolo, Stefano Corna, Veronica Valtolina, Claudio Bordignon
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 11 (2020)
Frontiers in Immunology, Vol 11 (2020)
The main challenge of adoptive therapy with Chimeric Antigen Receptor modified T cells (CAR T) is the application to the field of solid tumors, where the identification of a proper antigen has emerged as one of the major drawbacks to CAR T cell treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::541ef965aeaa81d83c0c5a8465e79d04
http://europepmc.org/articles/PMC7010926
http://europepmc.org/articles/PMC7010926
Autor:
Flavio Curnis, Francesca Nardelli, Barbara Valentinis, Giovanna Musco, Catia Traversari, Giacomo Quilici, Angelina Sacchi, Cristina Paissoni, Michela Ghitti, Alessandro Gori, Angelo Corti
Publikováno v:
Journal of medicinal chemistry (2018).
info:cnr-pdr/source/autori:F. Nardelli, C. Paissoni, G. Quilici, A. Gori, C. Traversari, B. Valentinis, A. Sacchi, A. Corti, F. Curnis, M. Ghitti, G. Musco/titolo:Succinimide-based conjugates improve IsoDGR cyclopeptide affinity to avb3 without promoting integrin allosteric activation/doi:/rivista:Journal of medicinal chemistry/anno:2018/pagina_da:/pagina_a:/intervallo_pagine:/volume
info:cnr-pdr/source/autori:F. Nardelli, C. Paissoni, G. Quilici, A. Gori, C. Traversari, B. Valentinis, A. Sacchi, A. Corti, F. Curnis, M. Ghitti, G. Musco/titolo:Succinimide-based conjugates improve IsoDGR cyclopeptide affinity to avb3 without promoting integrin allosteric activation/doi:/rivista:Journal of medicinal chemistry/anno:2018/pagina_da:/pagina_a:/intervallo_pagine:/volume
The isoDGR sequence is an integrin-binding motif that has been successfully employed as a tumor-vasculature-homing molecule or for the targeted delivery of drugs and diagnostic agents to tumors. In this context, we previously demonstrated that cyclop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b13e05e5b77f0c2110d4103b4e193caf
https://doi.org/10.1021/acs.jmedchem.8b00745
https://doi.org/10.1021/acs.jmedchem.8b00745
Autor:
Francesca, Nardelli, Cristina, Paissoni, Giacomo, Quilici, Alessandro, Gori, Catia, Traversari, Barbara, Valentinis, Angelina, Sacchi, Angelo, Corti, Flavio, Curnis, Michela, Ghitti, Giovanna, Musco
Publikováno v:
Journal of medicinal chemistry. 61(17)
The isoDGR sequence is an integrin-binding motif that has been successfully employed as a tumor-vasculature-homing molecule or for the targeted delivery of drugs and diagnostic agents to tumors. In this context, we previously demonstrated that cyclop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7a32bb7aeae4abfc282095a4ee5071b2
https://pubmed.ncbi.nlm.nih.gov/30152697
https://pubmed.ncbi.nlm.nih.gov/30152697
Autor:
Claudia Asperti, Paola Di Matteo, Catia Traversari, Barbara Valentinis, Gian Paolo Rizzardi, Dan Zhou, Manuela Cota, Chiara Zucchelli, Simona Porcellini, Gianpiero Garau, Nilla Roberta Avanzi, Massimo Degano, Giovanna Musco
Publikováno v:
'International Journal of Molecular Sciences ', vol: 20, pages: 4511-1-4511-22 (2019)
International Journal of Molecular Sciences, Vol 20, Iss 18, p 4511 (2019)
International Journal of Molecular Sciences
Volume 20
Issue 18
International Journal of Molecular Sciences, Vol 20, Iss 18, p 4511 (2019)
International Journal of Molecular Sciences
Volume 20
Issue 18
NGR-hTNF is a therapeutic agent for a solid tumor that specifically targets angiogenic tumor blood vessels, through the NGR motif. Its activity has been assessed in several clinical studies encompassing tumors of different histological types. The dru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd6c511677049392198a2073d337f538
https://epn-library.esrf.fr/flora/jsp/index_view_direct_anonymous.jsp?record=doc:PUB_ESRF:53926
https://epn-library.esrf.fr/flora/jsp/index_view_direct_anonymous.jsp?record=doc:PUB_ESRF:53926
Autor:
Silvia Mari, Andrea Spitaleri, Giovanna Musco, Claudia Asperti, Gian Paolo Rizzardi, Catia Traversari, Barbara Valentinis, Michela Ghitti
Publikováno v:
Angewandte Chemie International Edition. 51:7702-7705
Ain't got that swing(-out): The cyclopeptide isoDGR is emerging as a new αvβ3 integrin binding motif. Agreement between the results of computational and biochemical studies reveals that isoDGR-containing cyclopeptides are true αvβ3 integrin antag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08851f826baace6781178759f0cd47b5
https://doi.org/10.1002/anie.201202032
https://doi.org/10.1002/anie.201202032
Autor:
Elena Tiziano, Catia Traversari, Claudia Asperti, Claudio Bordignon, Barbara Valentinis, Patrizia Mangia, Gian-Paolo Rizzardi, Simona Porcellini
NGR-TNF is a vascular targeting agent in advanced clinical development, coupling tumor necrosis factor-α (TNF) with the CNGRCG peptide, which targets a CD13 isoform specifically expressed by angiogenic vessels. Antitumor efficacy of NGR-TNF has been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a87bcca0b623c2f5799509b1531dd6f6
https://europepmc.org/articles/PMC4589061/
https://europepmc.org/articles/PMC4589061/
Autor:
Catia Traversari, Francesca Sanvito, Gian Paolo Rizzardi, Elena Tiziano, Claudio Doglioni, Patrizia Mangia, Barbara Valentinis, Simona Porcellini, Paola Di Matteo, Claudio Bordignon
Tumor vessels are an attractive target for cancer therapy, including metastasis treatment. Angiogenesis inhibitors targeting the VEGF signalling pathway have proven to be efficacious in preclinical cancer models and in clinical trials. However, angio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6270a93f402e2c6c847cd78fad8c86c0
Autor:
Marco Bianchi, Reinhard E. Voll, Bernd Arnold, Peter P. Nawroth, Ingrid E. Dumitriu, Martin Herrmann, Angelo A. Manfredi, Paramita Baruah, Barbara Valentinis, Patrizia Rovere-Querini
Publikováno v:
Scopus-Elsevier
High mobility group box 1 (HMGB1) is an abundant and conserved nuclear protein that is released by necrotic cells and acts in the extracellular environment as a primary proinflammatory signal. In this study we show that human dendritic cells, which a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad2f47c007e688e00c972881c3c6a8f7
https://doi.org/10.4049/jimmunol.174.12.7506
https://doi.org/10.4049/jimmunol.174.12.7506